Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Investor Day (August 2025)
21 slides from Expres2ion Biotech Holding Ab's investor day presentation, Aug 29, 2025
Slide 1: Innovative vaccines for a healthier world
The deadliest threat in wo deserves a better defence Innovative vaccines for a healthier world Bent Frandsen — CEO 29 August 2025 O: EXPRS2 —— Hosted by Hearings
Slide 2: Disclaimer
expreScion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentati
Slide 3: Breast cancer is still killing 685,000 women every year
Breast Cancer is still killing 685,000! women exprgre every year — will we let it continue? HER2 expression Annual new breast cancer cases’8 * 2.3 million women diagnosed each year' — breast H HER2 | cancer is the most common cancer worldwide He receptor { Uae) * 685,000 deaths annually! — the leadi
Slide 4: Presentation with media with solid fill
Presentation with media with solid fill
Slide 5: Understanding ES2B-C001's Advantage over Monoclonal Antibodies
Understanding ES2B-CO01's Advantage over Monoclonal Antibodies MONOCLONAL COMBINATION OF ES2B-C001: ANTIBODY DRUGS mAb DRUGS POLYCLONAL ANTIBODY RESPONSE Weaker inhibition Medium inhibition Strong and durable inhibition
Slide 6: Our Platform Solution: First Vaccine to Target All of HER2
Our Platform Solution: First Vaccine to aexPrescion Target All of HER2 (4 Domains) with a VLP oNcep tual commerci Y¥ Used in lal VLPs! (all 4 extra-cellular domains) ExpreS2” platform Generates a broad immune attack @ (polyclonal antibodies against multiple HER2 epitopes) (= 50 HER2 molecules) VLP t
Slide 7: Advantage of ES2B-C001 over monoclonal antibodies: broad polyclonal response
Vehicle Vehicle Vehicle ES2B-C001 ES2B-C001 ES2B-C001 ES2B-C001 ES2B-C001 ES2B-C001 + adjuvant + adjuvant + adjuvant • A further advantage of ES2B-C001 over monoclonal antibodies was the induction of a broad polyclonal immune response, comprising all IgG isotypes, including IgG2a, IgG2b and IgG3, wh
Slide 8: Lung metastases
• 600 500 Lung metastases 400 (red line = median) A further advantage of ES2B-C001 over monoclonal antibodies was the induction of a broad polyclonal immune response, comprising • all IgG isotypes, including IgG2a, IgG2b and IgG3, which were previously found to be instrumental in the protection 300
Slide 9: Tumor volume
• 2.5 Tumor volume (cm3) 2.0 Mean ± SEM 1.5 • A further advantage of ES2B-C001 over monoclonal antibodies was the induction of a broad polyclonal immune response, comprising all IgG isotypes, including IgG2a, IgG2b 1.0 * and IgG3, which were previously found to be instrumental in the protection of t
Slide 10: Phase I (First-in-Human) Underway - First Patients Dosed
Phase | (First-in- Human) Underway - First STOLE a Patients Dosed Open-label, dose escalation Phase | in metastatic HER2+ and HER2-low breast cancer Medical University of Vienna activated; adding 2 new Austrian sites Up to 27 planned; includes escalation and expansion cohorts Escalating doses; expan
Slide 11: Accelerating Recruitment & Next Steps
expreSceion BIOTECH Accelerating Recruitment & Next Steps De-risking enrolment, gaining momentum Regulatory Approval Vienna Network New sites nN
Slide 12: Significant Market Opportunity
Significant Market Opportunity ES2B-C001 is a First-in-Class breast cancer immunotherapy, targeting the entire extracellular domain of HER2 Patient distribution by region and cancer type! 1,000,000 Expansion to additional || patient grus 600,000 400,000 — P| — 200,000 , x = HER2+ BC HER2-low BC HER2
Slide 13: We Are a Platform-Based Vaccine Company
expreSceion We Are a Platform-Based Vaccine Company a. Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform Target Pre-clinical DISEASE Project/Target ID Identification | Pharmacology | cGMP / Tox Phase Ill Collaboration Partner 100% x Breast Cancer! expreszi
Slide 14: Strategy: Building Long-Term Value on Four Pillars
Strategy: Building Long-Term Value on Four Pillars * First-in-human study of ES2B- C001 underway + First patients dosed Advancing our proprietary pipeline + Oxford malaria vaccine in Phase II + Other programs include Nipah and influenza (Copenhagen, INDIGO) Intensifying vaccine collaborations Growin
Slide 15: Clinical & Pipeline Catalysts
expreSceion BIOTECH SN Clinical & Pipeline Catalysts ES2B-CO001 + Safety readout expected mid-2026 * Immunogenicity & early efficacy signals (if observable at this early stage) in late 2026 + Oxford Malaria Trials: Phase Ilb data in Q2 2026 + Nipah Vaccine Lead Candidate Selection: H2 2025 Strategic
Slide 16: TO Warrants — Investor Upside & Company Funding
TO 11 Warrants — Investor Upside & Company = °*?"*°é28 Funding * Exercise Period * Subscription period: Sept 18 — Oct 2, 2025 . : : 9, : Exercise price set at 70% of VWAP during Sept 1-12 (min SEK 4.44, max SEK sept 1-12: Septis - Oct After Oct 2: 70.00) Pricing period . ‘period ton Share Delivery *
Slide 17: Net sales and other operating income
Net sales Other operating income 1Q23 3Q23 1Q24 3Q24 1Q25 1Q23 3Q23 1Q24 3Q24 1Q25
Slide 18: Cost Discipline & Runway: Lean Operations
Cost Discipline & Runway: Lean Operations SEK ‘000s Operating expense () -10,000 eS 18,100 -20,000 35% YOY -30,000 -40,000 123 3Q23. 1024 3Q24 1Q25 expreSeiaon BIOTECH R&D costs (external) : a -5,000 | I | | -10,000 —— -15,000 -20,000 Volatile & dependent upon pipeline activities 1Q23 2Q23 3Q23 4Q23
Slide 19: 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25
• 88 • 82 77 76 72 69 • 60 58 58 • 49 • 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25
Slide 20: Key Risks & How We Mitigate Them
Key Risks & How We Mitigate Them Clinical Trial Risk + Risk:Enrolment pace and early- phase timing uncertainty + Mitigation: Expanded sites (Vienna +2 new) and dose-escalation design help address enrolment timing uncertainty; first patients already Partnership Dependence + Risk: External programs (m
Slide 21: Q&A
expreSceion 5 BIOTECH Q&A EXPRS2 Innovative vaccines for a F investor@ expres2ionbio.com https://investor. expres2ionbio.com
ExpreS2ion Biotech Holding — Investor Day (August 2025) on 6ix